ストックスクリーナーアプリを入手
36.17
5.51%
-2.11
アフターアワーズ：
35.60
-0.57
-1.58%
前日終値:
$38.28
開ける：
$38.01
24時間の取引高:
12.17M
Relative Volume:
0.50
時価総額：
$8.37B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
69.28
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+4.33%
1か月 パフォーマンス:
+38.11%
6か月 パフォーマンス:
+2.00%
1年 パフォーマンス:
-25.30%
1日の値動き範囲:
$36.14
$38.59
1週間の範囲:
$34.75
$39.05
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
36.17 | 8.86B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Technical Reactions to HIMS Trends in Macro Strategies - Stock Traders Daily
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance UK
Form 4 Hims Hers Health Inc For: 7 July By Investing.com - Investing.com Canada
Hims & Hers CFO Okupe sells $261k in stock By Investing.com - Investing.com Canada
Hims & Hers (NYSE: HIMS) CFO exercises options and sells 7,163 shares under 10b5-1 plan - Stock Titan
Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand - Investing.com
HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish - Stocktwits
Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide Questions - Yahoo Finance
HIMS Stock Rises Overnight: CEO Shrugs Off Wild Swings, Bets On ‘Gold Standard’ Of Healthcare Over Next Decade - Stocktwits
Hims & Hers Health Inc (HIMS) Stock Up 4.0% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Form 144 Hims & Hers Health For: 6 July By Investing.com - Investing.com Canada
[144] Hims & Hers Health, Inc. SEC Filing - Stock Titan
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner - MarketBeat
HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’ - Stocktwits
Hims & Hers Health stock falls as insider files to sell shares - Investing.com
HIMS Breakout Signals Structural Business Transformation (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc at Morgan Stanley Technology, Media & Telecom Conference Transcript - GuruFocus
Hims & Hers Health Inc Stock Baskets | XSWX:HIMS - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock News, Headlines & Updates - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock Price & 30 Year Financial Data - GuruFocus
Hims & Hers Health Inc Stock Operating Data - GuruFocus
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Hims & Hers Health, Inc.: Target Price Consensus and Analysts Recommendations | HIMS | US4330001060 - marketscreener.com
HIMS Stock Jumps 8% as JPMorgan Facility and Analyst Upgrades Fuel Rally - FXLeaders
Hims & Hers Health Enters Receivables Purchase Agreement with JPMorgan Chase Bank – Key Terms and Details - Minichart
Hims & Hers Establishes New $400 Million Receivables Facility - TipRanks
Hims & Hers Launches $400 Million Receivables Facility, Amends Revolver to Support Program - TradingView
Hims & Hers (HIMS) adds $400M receivables facility and amends credit deal - Stock Titan
HIMS Stock Surges as Canaccord Genuity Raises Price Target - GuruFocus
Hims & Hers Stock Surges as Analysts Lift Price TargetsHims & Hers Health (NYSE:HIMS) - Benzinga
Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review - TradingView
Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset - TechStock²
BofA raises Hims and Hers stock price target on FDA peptide review - Investing.com
Hims stock gains as FDA revives AdComs (HIMS:NYSE) - Seeking Alpha
HIMS Maintains by B of A Securities -- Price Target Raised to $3 - GuruFocus
HIMS Maintained by Canaccord Genuity -- Price Target Raised to $40 - GuruFocus
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Hims & Hers stock rises after Canaccord price target hike - Investing.com
Hims & Hers Health Price Target Raised to $40.00/Share From $32.00 by Canaccord Genuity - Moomoo
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $29.27, Implies 16% Downside - TradingView
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Canaccord raises Hims and Hers stock price target on weight loss drugs - Investing.com Canada
Hims & Hers Health Inc (HIMS) Shares Surge 3.8% -- What GF Score of 81 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Lost Money on Hims & Hers Health, Inc. (HIMS)? Join Class Action Before August 25, 2025Contact Levi & Korsinsky - The National Law Review
Join Class Action to Recover Losses from Hims & Hers Health, Inc - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Hims & Hers - The National Law Review
Hims & Hers Health Stock (HIMS) Opinions on Business Reacceleration and Analyst Upgrades - Quiver Quantitative
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
1.95%
大文字化:
|
ボリューム (24 時間):